A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2-Reference-Cited by-同舟云学术

A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2

Published:2021-12-08 Issue: Volume: Page:
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Zhang Qian,Zhou Renpeng,Yang Jingjing,Dou Changlin,Gan Tianyi,Liu Fujia,Hu Baihui,Song Deyong,Lu Chao,Hu Wei^ORCID

Funder

National Major Scientific and Technological Special Project

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-021-00572-x.pdf

Reference12 articles.

1. World Health Organization. WHO coronavirus (COVID-19) dashboard. 2021. https://covid19.who.int.

2. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. 2021. https://www.covid19treatmentguidelines.nih.gov/.

3. Guideline Development Group. Therapeutics and COVID-19: living guideline. Geneva: World Health Organization.

4. FDA. Emergency Use Authorization (EUAs). 2021. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs.

5. Song D, Wang W, Dong C, et al. Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2. Commun Biol. 2021;4:500.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002–an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults;BMC Infectious Diseases;2023-06-27

2. Research and development of Chinese anti-COVID-19 drugs;Acta Pharmaceutica Sinica B;2022-12

3. Review of the Chinese Landscape in Phase 1 Clinical Trials for Noncancer Innovative Drugs Over 2015 to 2020;Clinical Pharmacology in Drug Development;2022-06-16

4. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?;mAbs;2022-02-27